The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
Open accessAbstract
Background Median overall survival for patients with metastatic soft tissue sarcoma is 12 to 16 months. Olaratumab is a human anti–platelet-derived growth factor receptor α monoclonal antibody which has antitumour activity in human sarcoma xenografts. Methods We conducted an open-label phase 1b, randomised, phase 2 study of doxorubicin ± olaratumab in patients with unresectable/metastatic soft tissue sarcoma. The phase 1b primary endpoint was safety; the phase 2 primary endpoint was progression-free survival using a two-sided alpha level of 0·2 and statistical power of 0·8. This study was registered with ClinicalTrials.gov, number NCT01185964. Findings Fifteen patients were enrolled and treated with olaratumab+doxorubicin in the phase 1b portion; 133 patients were randomised (66 to olaratumab+doxorubicin; 67 to doxorubicin) in the phase 2 portion, 129 of whom (97%) received at least one dose of study treatment (64 olaratumab+doxorubicin; 65 doxorubicin). Median progression-free survival in phase 2 was 6·6 months (95% confidence interval [CI], 4·1–8·3) with olaratumab+doxorubicin and 4·1 months (95% CI, 2·8–5·4) with doxorubicin (stratified hazard ratio [HR], 0·672; 95% CI, 0·442–1·021; p=0·0615). Median overall survival was 26·5 months (95% CI, 20·9–31·7) with olaratumab+doxorubicin and 14·7 months (95% CI, 9·2–17·1) with doxorubicin (stratified HR, 0·463; 95% CI, 0·301–0·710; p=0·0003). Adverse events more frequent with olaratumab+doxorubicin vs doxorubicin alone included neutropenia (38 [59%] vs 25 [39%]), mucositis (34 [53%] vs 23 [35%]), nausea (47 [73%] vs 34 [52%]), vomiting (29 [45%] vs 12 [19%]), and diarrhea (22 [34%] vs 15 [23%]). Febrile neutropenia of grade ≥3 was similar in both groups (olaratumab plus doxorubicin 8 (13%) vs doxorubicin 9 (14%). Interpretation This study of olaratumab with doxorubicin in patients with advanced soft tissue sarcoma met its predefined primary endpoint for progression-free survival and achieved a highly significant improvement of 11·8 months in median overall survival (P=0·0003; HR 0·46). Funding Eli Lilly and Company.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Judson, I., Verweij, J., Gelderblom, H., Hartmann, J. T., Schöffski, P., Blay, J.-Y., Kerst, J. M., Sufliarsky, J., Whelan, J., Hohenberger, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70063-4 · Cited by 1,183
Ng, F., Boucher, S., Koh, S., Sastry, K. S. R., Chase, L., Lakshmipathy, U., Choong, C., Yang, Z., Vemuri, M. C., Rao, M. S., et al. (2008) · Blood · doi:10.1182/blood-2007-07-103697 · Cited by 580
Le Cesne, A., Judson, I., Crowther, D., Rodenhuis, S., Keizer, H. J., Van Hoesel, Q., Blay, J. Y., Frisch, J., Van Glabbeke, M., Hermans, C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2676 · Cited by 256
Lorigan, P., Verweij, J., Papai, Z., Rodenhuis, S., Le Cesne, A., Leahy, M. G., Radford, J. A., Van Glabbeke, M. M., Kirkpatrick, A., Hogendoorn, P. C. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7717 · Cited by 256
Involvement of platelet-derived growth factor in disease: development of specific antagonists
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)80010-5 · Cited by 202
Management of soft-tissue sarcomas: an overview and update
Singer, S., Demetri, G. D., Baldini, E. H., & Fletcher, C. D. (2000) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00016-4 · Cited by 179
Movva, S., Wen, W., Chen, W., Millis, S. Z., Gatalica, Z., Reddy, S. K., von Mehren, M., & Tine, B. A. V. (2015) · Oncotarget · doi:10.18632/oncotarget.3498 · Cited by 132
Loizos, N., Xu, Y. C., Huber, J., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0114 · Cited by 118
Cited by
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy096 · Cited by 1,614
Self-citationTawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759
Self-citationAnlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Shen, G., Zheng, F., Ren, D., Du, F., Dong, Q., Wang, Z., Zhao, F., Ahmad, R., & Zhao, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0664-7 · Cited by 658
Metadata
- Authors
- Tap, W. D., Jones, R. L., Van Tine, B. A., Chmielowski, B., Elias, A. D., Adkins, D., Agulnik, M., Cooney, M. M., Livingston, M. B., Pennock, G., Hameed, M. R., Shah, G. D., Qin, A., Shahir, A., Cronier, D. M., Ilaria, R., Conti, I., Cosaert, J., & Schwartz, G. K.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 388
- Issue
- 10043
- Pages
- 488-497
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2413552560
- Cited by
- 584
- References
- 14
- FWCI
- 84.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(16)30587-6
- The paper
- Tap, W. D., Jones, R. L., Van Tine, B. A., Chmielowski, B., Elias, A. D., Adkins, D., Agulnik, M., Cooney, M. M., Livingston, M. B., Pennock, G., Hameed, M. R., Shah, G. D., Qin, A., Shahir, A., Cronier, D. M., Ilaria, R., Conti, I., Cosaert, J., & Schwartz, G. K. (2016). Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. The Lancet. https://doi.org/10.1016/s0140-6736(16)30587-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.